Investors

At this page you will find information about Arcomas business and financial position. The information at this page is aimed at shareholders and potential investors.

Intervju med Arcomas VD Sanna Rydberg om kvartalsrapporten för Q2 2022.

Erik Penser Bank har den 18/8 2022 gjort en intervju med Arcomas VD, Sanna Rydberg där hon berättar om kvartalrapporten för andra kvartalet 2022.

Intervjun finns att se live på Erik Pensers YouTubekanal, Penser Play.

 

Årsredovisning 2021

Klicka på bilden eller länken nedan för att ladda ner vår årsredovisning för 2021 som PDF.

Årsredovisning 2021

Intervju med Arcomas VD Sanna Rydberg.

Se intervjun med vår VD Sanna Rydberg från Erik Penser Banks bolagsdag 25 november. Sanna berättar här mer om Arcoma, vårt fokus inom produktutveckling, hur försäljningsprocessen ser ut och hur hon ser på framtiden och kommande tillväxt.

Investor news


Intervju med Arcomas VD Sanna Rydberg om kvartalsrapporten för Q2 2022.

Erik Penser Bank har den 18/8 2022 gjort en intervju med Arcomas VD, Sanna Rydberg där hon berättar om kvartalrapporten för andra kvartalet 2022. I…

Senaste analysen av Arcoma – Ett kvartal enligt förväntningar

“Arcoma redovisar stark bruttomarginal om 47% (39%) vilken stärks mot bakgrund av bl.a. valutaeffekter och geografisk försäljningsmix.”…

Årsredovisning 2021

Årsredovisning för 2021 är nu publicerad. Ladda ner PDF

Senaste analysen av Arcoma – Marknaden fortsatt svag i Q4

“Omsättningen för Q4 uppgick till 21,2 mkr (30,2 mkr) och Arcoma fortsätter därmed vara belastade av en marknad där kunder fortsätter vara re…

Senaste analysen av Arcoma – Avvaktande marknad under Q3

“Vi ser dock fortsatt en stark underliggande marknad med en stark förväntad tillväxt kommande år, och bolaget är välpositionerat med starka s…

Company presentations & interviews

  • 2021-11-16: Arcomas VD Sanna Rydberg intervjuas av aktieanalytiker Hjalmar Jernström på Erik Penser Bank. Se intervjun.

  • 2021-10-07: Sanna Rydberg och Linda Ungsten presenterar Arcoma på Erik Penser Banks temadag om Medicinteknisk mjukvara. Se presentationen.
  • Årsstämma 2020 – Sanna Rydberg, VD Arcoma sammanfattar 2020 och blickar framåt. Se video
  • 2021-05-25: Sanna Rydberg presenterar Arcoma på Erik Penser Banks temadag om Medicinsk Bildteknik & Diagnostik. Se presentationen.
  • 2021-02-22: Arcomas VD Sanna Rydberg intervjuas av aktieanalytiker Hjalmar Jernström på Erik Penser Bank. Länk till video.
  • 2020-11-25: Den 25 november 2020 presenterade Arcomas nya VD, Sanna Rydberg bolaget på Erik Penser Banks bolagsdag samt deltog på en intervju. Länk till Presentation och intervju. 

  • 2020-03-12: Arcoma presenterar på Stockholm Corporate Finance (SCF) tolfte Life Science-seminarium. Videosändning

Interested in investing in Arcoma?

See our company presentation and learn more about Arcoma and our market.

Board of directors

Lars Kvarnhem – Chairman

Lars Kvarnhem, born in 1972, has approximately 20 years of experience in global management and business development of companies and business processes within the MedTech industry.

Previous operational roles have been, among others:

  • CEO and main owner of the MedTech company Anmedic AB, active in anesthesia and intensive Care.
  • President and CEO for Human Care (publ) in healthcare products.
  • Operational Chairman of the MedTech division at Medcap (publ).

Works exclusively as an investor, primarily in the field of Medical Technology. Today Lars holds several board assignments which includes chairman of the board of Arcoma AB (publ), Stille (publ), Absorbets AB, Absorbest Holding AB, Swevet AB, Swevet Holding AB, Reison Medical AB, Part Production AB, Priego AB and Ovon AB, better known as MrCap. Board member Cavis Technologies.

Year of birth 1972
Chairman since 2017
Shares 1 306 925 (1 306 925) through Priego AB

Other assignments: Chairman of the board of Swevet AB, Reison Medical AB and Ovon AB, better known as MrCap.

Lars is dependent in relation to major shareholders.

Mats Thorén – Board member

Mats Thorén has extensive experience in the medical technology sector, including with Handelsbanken Capital Markets as an account executive for the health sector in Corporate Finance, as an analyst in the biotechnology and medical technology at Enskilda Securities as well as Partner at Catella Healthcare AB. Previous board appointments include inter alia C-Rad AB, Cellartis AB and MIP Technologies AB.

Year of birth 1971
Member/deputy 2012/2010
Shares 668 000 directly and through Vixco Capital AB Independent in relation to major shareholders

Other assignments Board member of: Pulsetten AB, Vixco Capital AB, Arcoma Incentive AB and board substitute for Eggelbertus Holding AB.

Mats is independent in relation to major shareholders.

Jan Wahlström – Board member

Jan Wahlström, born in 1967, has extensive experience from leading positions at international companies in medical technology, life science and laboratory instruments. He is the CEO of Mabtech AB since May 2022.

Previous assignments Jan has held are CEO of Elos Medtech, CEO of Biolin Scientific and Chairman of the Board of Insplorion AB.

Year of birth 1967
Member since 2022
Shares None

Other assignments: Jan Wahlström’s other assignments include: Chairman of the Board of Mablax AB, Board member of Alexam AB, Mabtech AB, CEO of Mabtech AB and Mabtech group holding AB.

Jan Wahlström does not hold any shares in the company and is considered to be independent both in relation to the company, its management and in relation to its major shareholders.

Management team

Sanna Rydberg – Verkställande Direktör

Sanna Rydberg har ca 20 års erfarenhet från ledande positioner, senast som VD för Eurofins BioPharma Product Testing Sweden AB där hon varit anställd som VD. Verksamheten omfattar kemiska och mikrobiologiska analyser till Läkemedel- och Medicinteknikbolag.

Dessförinnan som verksamhetschef för Healthcare Nordeuropa på Linde (tidigare AGA). Verksamheten omfattade hela kedjan från tillverkning till försäljning och distribution av både läkemedel och medicintekniska produkter. Samt två kliniker för vård av patienter med respiratoriska problem.

Sanna Rydberg har en Fil.kand. i Analytisk Kemi, Uppsala Universitet.

Sanna är även ledamot i styrelsen för Observe Medical ASA.

Year of birth 1969
Employed since 2020
Other assignments None
Own and related party shares 7000
Contact info sanna.rydberg@arcoma.se

Johan Dahlberg – CFO

Johan Dahlberg has a master’s degree from Lund University and experience in most roles in finance, such as Business Controller, Accounting Manager and Finance Manager.

Most recently, he came from a business-related role at BIMobject, where he mainly worked with business follow-up. Prior to BIMobject, Johan worked for seven years at Qlik, a leading company in Business Intelligence, including the role of Finance Manager for Qlik’s Nordic sales companies.

Year of birth 1984
Employeed since 2022
Other assignments None
Own and related party shares 0
Contact info johan.dahlberg@arcoma.se

Johan Henningsson – R&D Manager

Johan Henningsson has a bachelor in mechanical engineering at Linné University. Johan has a background as a mechanical engineer at Arcoma.

Year of birth 1971
Employed since 1994, in current position since 2014.
Other assignments None
Own and related party shares 7254
Contact info johan.henningsson@arcoma.se

Linda Ungsten – Product Manager

Linda holds a Master of Science in Engineering from Linköping University of Technology and experience as product manager at Bombardier Transportation and from employment within Radiological Physics at Sahlgrenska University Hospital.

Year of birth 1974
Employed since 2008, in her current position since 2011
Other assignments None
Own and related party shares None
Contact info linda.ungsten@arcoma.se

Nicklas Johansson – Operations Manager

Nicklas Johansson has background as manufacturing manager, and workshop manager at Fläkt Woods and production planner at Arcoma AB.

Year of birth 1967
Employed since 2003, in current position since 2016
Other assignments None
Own and related party shares 14 000
Contact info nicklas.johansson@arcoma.se

Frida Robbe – Marketing Manager

Frida Robbe is educated in marketing, web development, graphic design and copywriting and has experience from marketing of medical and healthcare products for more than 10 years.

Year of birth 1985
Employed since 2019
Other assignments None
Own and related party shares 280
Contact info frida.robbe@arcoma.se

Jesper Lindroos – Purschasing Manager

Jesper Lindroos has extensive experience from the medical technology and manufacturing industry and comes most recently from Getinge Group where he held the position as Chief Project Manager. He has a Master of Science in Mechanical Engineering from Lund University and joined Arcoma during 2020.

Year of birth 1984
Employed since 2020
Other assignments None
Own and related party shares None
Contact info jesper.lindroos@arcoma.se

Henrik Blomdahl – Quality Manager

Henrik Blomdahl has over 20 years of experience in the medical technology industry. Most recently, Henrik comes from Invacare Rea AB, where he had the role of QA/RA Manager Nordics.

Prior to that he worked as a quality technician at Getinge Disinfection in Växjö, focusing on supplier quality, project management and internal and external audits.

Employed since 2021
Other assignments None
Own and related party shares None
Contact info henrik.blomdahl@arcoma.se

Share information

According to Articles of Association of Arcoma AB:

  • The share capital shall not be less than 12 000 000 Kronor and no more then 48 000 000 Kronor.
  • The number of shares shall not be less than 6 000 000 shares and no more then 24 000 000 shares.
  • Registered share capital is 26 104 120 kronor.
  • The shares is issued under the Companies Act and is denominated in Swedish kronor.
  • There is only one type of share. All shares carry equal rights to the Company’s assets and results, and are entitled to one vote at the Annual General Meeting. One share equals one vote.
  • Company’s share register is kept by Euroclear Sweden AB (former VPC AB), Box 7822, 103 97 Stockholm. Shareholders of the Company will receive no physical share. All transactions with the Company’s shares are done electronically through authorized banks and broker- dealers. Newly issued shares will be registered in person in electronic format.
  • Issuer and the account operator is Erik Penser Bank, Apelbergsgatan 27, Box 7405, 103 91 Stockholm
  • The shares ISIN-Code is SE0006219176
  • The LEI code is 549300C0DH9EESDQUA52

Shareholders

Register Date: 2022-06-30

Main Share
Holders

 

Percentage of
issued shares

Linc AB

 

25,25%

Sunstone Life Science Ventures Fund II K/S

 

25,00%

Priego AB

 

10,01%

Avanza Pension

  5,56%

Mats Thorén via bolag

  5,12%
     
     

We develop, produce and provide complete radiology solutions worldwide with the mission to improve care for the patient and work environment for the user.